Molecular Docking Assessment of Efficacy of Different Clinically Used Arsenic Chelator Drugs

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="396768.fig.003a" src="https://static.hindawi.com/articles/jcm/volume-2013/396768/figures/396768.fig.003a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Albumin</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="396768.fig.003b" src="https://static.hindawi.com/articles/jcm/volume-2013/396768/figures/396768.fig.003b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>PDH</td></tr></table></td></tr></table>

<table><i>α</i>-LA binding with albumin (a) and PDH (b).</table>

Journal of Computational Medicine

fig3

Figure 3

Figure 3: Molecular Docking Assessment of Efficacy of Different Clinically Used Arsenic Chelator Drugs 